Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Nyxoah to Release Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023
Mont-Saint-Guibert, Belgium – March 8, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the fourth quarter and full year 2022 on Wednesday, March 22, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
Investors interested in listening to the conference call may do so by registering for a unique personal PIN at the following link: Conference Registration (vevent.com). A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.nyxoah.com/events.
About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.
Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.
For more information, please visit http://www.nyxoah.com/.
Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.
Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Galapagos and NovAliX enter into an integrated drug discovery collaboration30.3.2023 22:30:00 CEST | Press release
Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, FranceNovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access necessary expertise and resources through a five year-collaboration agreementTransaction in the context of Galapagos’ strategic reset announced in 2022; closing expected in July 2023 Mechelen, Belgium and Strasbourg, France; 30March 2023, 22.01 CET; GalapagosNV (Euronext & NASDAQ: GLPG)and NovAliXtoday announceda strategic collaborationin which Galapagos’ research and discovery capabilities and exclusively related employees based in Romainville, France, will be transferred toNovAliX, a drug discovery-focused Contract Research Organization. The agreement follows Galapagos’ renewed focus on its key therapeutic areas of oncology and immunology, and the strategic reorientationof the company into a fit-for-purpose
ResMed Chief Administrative Officer and Global General Counsel to Retire30.3.2023 22:05:00 CEST | Press release
ResMed to conduct an internal search for a successor general counselAmy Wakeham appointed Chief Communications and Investor Relations Officer, will join ResMed’s executive leadership team SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today that David Pendarvis, chief administrative officer, global general counsel, and secretary, plans to retire, effective June 30, 2023. He will remain in a consulting role with ResMed through December 31, 2023. ResMed will conduct an internal search for the successor to Pendarvis’ legal roles and expects to name a new global general counsel and secretary well ahead of David’s retirement date to ensure a smooth and seamless transition. Amy Wakeham, ResMed’s current Vice President of Corporate Communications & Investor Relations, has been appointed Chief Communications and Investor Relations Officer to succeed Pendarvis in his role leading corporate public affairs; she will report to the Office of the CEO and will jo
The New Zealand Qualifications Authority and World Education Services Partner on Qualifications Recognition for Migrants with International Education30.3.2023 22:00:00 CEST | Press release
WELLINGTON, New Zealand, March 30, 2023 (GLOBE NEWSWIRE) -- The New Zealand Qualifications Authority (NZQA) and World Education Services (WES) have signed an agreement to streamline qualifications assessment for migrants to New Zealand who hold credentials from another country. Under the agreement, WES will provide qualification verification services to immigration applicants to New Zealand. “NZQA is delighted to work with WES to ensure a more efficient process for recognising the educational qualifications of those who want to make New Zealand home,” said NZQA Chief Executive Dr Grant Klinkum. “WES has been verifying academic credentials for decades, and we’ll leverage this experience to the benefit of New Zealand and our newest residents.” The new WES Global Records Verification Report for NZQA is designed to expedite services for individuals who qualify for resident visas under the country’s skilled migrant category. This is part of a broader push to strengthen the nation’s economy.
LEADING EDGE MATERIALS ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD WEDNESDAY, APRIL 26, 202330.3.2023 22:00:00 CEST | Press release
LEADING EDGE MATERIALS ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD WEDNESDAY, APRIL 26, 2023 Vancouver, March30, 2023 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Corporation”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) announces that its Annual General Meeting of Shareholders (the “Meeting”) will be held at 14th Floor, 1040 West Georgia Street, Vancouver, British Columbia, V6E 4H1 on Wednesday, April 26, 2023, at 9:00 am (Vancouver Time), for the following purposes: To receive the Chief Executive Officer’s Report to the shareholders of the Corporation; To receive and consider the financial statements of the Corporation as at and for the year ended October 31, 2022, together with the report of the auditors thereon; To fix the number of directors of the Corporation to be elected at the Meeting; To elect the directors of the Corporation for the ensuing year; To appoint the auditors of the Corporation for the ensuing year and to authorize t
Leading Edge Materials CEO's Report fo the Shareholders30.3.2023 22:00:00 CEST | Press release
LEADING EDGE MATERIALS CEO’S REPORT TO THE SHAREHOLDERS Stockholm, March 30, 2023 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) provides a letter from the Chief Executive Officer. CEO’S REPORT TO THE SHAREHOLDERS The past year has not been short of geopolitical turbulence and macro-economic challenges. As the pandemic crisis has subsided, the war in Ukraine, rising inflation and recent bank failures have added to the tension. And of course, the impacts of climate change remain a high priority on political agendas. Our vision, materials for change, is right in the middle of these societal challenges. A change in the energy system towards renewables and energy storage, electrified mobility solutions and resilient and sustainable supply-chains will need new materials and new sources for those materials. This is where the projects we have and the work we do on them becomes critically important. G